MedTrace Logo

Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

NCT00162799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-06-23

No results posted yet for this study

Summary

To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

Conditions

Interventions

DRUG

Triflusal (DCI)

Sponsors & Collaborators

  • J. Uriach and Company

    lead INDUSTRY

Principal Investigators

  • Jose Manuel Fernández del Real, Dr · Unidad Diabetología. Serv Endocrino Hosp Josep Trueta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-07-31
Completion
2004-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162799 on ClinicalTrials.gov